Endoscopic camera firm Trice acquires carpal tunnel surgery guide company

Handshake business deal executives
According to the two companies, more than 600,000 carpal tunnel surgeries are performed each year in the U.S., and about a quarter of them are performed endoscopically. (Pixabay)

Trice Medical has moved to acquire S.E.G-Way Orthopaedics, to build a company that offers both diagnostic and surgical solutions for minimally invasive orthopedic procedures.

S.E.G-Way brings its endoscopic carpal tunnel release device to the deal, which supports minimally invasive surgeries for carpal tunnel syndrome, cubital tunnel syndrome, gastrocnemius equinus contracture and plantar fasciitis.

Meanwhile, Trice offers a fully disposable arthroscopy camera through its Mi-eye device, as well as a lightweight, transportable ultrasound system. Financial details of the deal were not disclosed.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“We’re looking forward to integrating the SegWAY offerings and building on our combined strengths,” Jeffrey O’Donnell Sr., CEO of Trice Medical, said in a statement. “One of the areas we’re looking at is using our minimally invasive camera technology in the operating room as well.”

According to the two companies, more than 600,000 carpal tunnel surgeries are performed each year in the U.S., and about a quarter of them are performed endoscopically.

“In just over five years, growing at 30% to 40% year on year, we’ve created tremendous traction among orthopedic surgeons,” said Stuart Seymour, CEO and founder of S.E.G-Way, in the statement. “Teaming with Trice Medical, which is advancing technologies that involve cameras and ultrasound, rounds out our offering for those doctors.”

Last month, Malvern, Pennsylvania-based Trice closed an $18.3 million extension to its series C round, to help expand its global commercialization efforts and fund development of new products.

Suggested Articles

Thermo Fisher Scientific has begun early talks to take over Dutch diagnostics maker Qiagen, according to reports.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.

VistaGen responded to the failure of the ketamine-line drug by vowing to review all the data before deciding on next steps.